About Sleuth

Provides a machine learning-powered platform for biopharma analysts to interrogate clinical trial data from multiple sources, test hypotheses in real-time, and identify related trials. This streamlines data analysis workflows, enabling faster, data-driven decision-making and uncovering insights critical to investment and research strategies in the bioeconomy.

<problem> Biopharmaceutical analysts face challenges in efficiently interrogating vast amounts of clinical trial data from disparate sources. Traditional methods often involve manual data collection and analysis, leading to delays in identifying key insights and testing hypotheses. This can hinder timely decision-making in investment and research strategies. </problem> <solution> Sleuth provides a machine learning-powered platform designed to streamline data analysis workflows for biopharma analysts. The platform aggregates and structures over 100 million data points from diverse sources, including clinical trials, regulatory filings, patents, and conference transcripts, with a focus on global data, including data from China. Sleuth enables users to test hypotheses in real-time and identify related trials, facilitating faster, data-driven decision-making. Users can either leverage the AI software platform directly or partner with Sleuth analysts to receive tailored, presentation-ready reports and actionable insights. The platform's AI agents monitor data sources 24/7, ensuring users never miss critical market movements. </solution> <features> - AI-powered analysis of 100M+ biopharma data points, including hard-to-find data such as China pipeline activity, event transcripts, and analyst research - Proprietary structured database with drugs, clinical trials, deals, targets, and indications - AI software platform to build outputs and analyses, using the same tools as Sleuth analysts - Option to submit requests and receive back finished deliverables, such as polished reports and presentation-ready slides - Auditable citations for easy verification of responses and source data - Secure data handling, with options to upload internal data without training models or sharing data externally - API access available on a case-by-case basis </features> <target_audience> The primary target audience includes biopharmaceutical analysts, investment firms, and research teams who require efficient access to and analysis of comprehensive clinical trial data for competitive intelligence, investment decisions, and research strategies. </target_audience> <revenue_model> Sleuth is priced as an annual retainer, with specific pricing dependent on factors such as custom use cases and the number of licenses. </revenue_model>

What does Sleuth do?

Where is Sleuth located?

Sleuth is based in Los Angeles, United States.

When was Sleuth founded?

Sleuth was founded in 2023.

Location

Los Angeles, United States

Founded

2023

Employees

15 employees

Looking for specific startups?

Try our free semantic startup search

Sleuth

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

sleuthinsights.com 2K+

Founded 2023 – Los Angeles, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (15+)

No team information available. Click "Fetch founders" to run a focused founder search.

Company Description

Problem

Biopharmaceutical analysts face challenges in efficiently interrogating vast amounts of clinical trial data from disparate sources. Traditional methods often involve manual data collection and analysis, leading to delays in identifying key insights and testing hypotheses. This can hinder timely decision-making in investment and research strategies.

Solution

Sleuth provides a machine learning-powered platform designed to streamline data analysis workflows for biopharma analysts. The platform aggregates and structures over 100 million data points from diverse sources, including clinical trials, regulatory filings, patents, and conference transcripts, with a focus on global data, including data from China. Sleuth enables users to test hypotheses in real-time and identify related trials, facilitating faster, data-driven decision-making. Users can either leverage the AI software platform directly or partner with Sleuth analysts to receive tailored, presentation-ready reports and actionable insights. The platform's AI agents monitor data sources 24/7, ensuring users never miss critical market movements.

Features

AI-powered analysis of 100M+ biopharma data points, including hard-to-find data such as China pipeline activity, event transcripts, and analyst research

Proprietary structured database with drugs, clinical trials, deals, targets, and indications

AI software platform to build outputs and analyses, using the same tools as Sleuth analysts

Option to submit requests and receive back finished deliverables, such as polished reports and presentation-ready slides

Auditable citations for easy verification of responses and source data

Secure data handling, with options to upload internal data without training models or sharing data externally

API access available on a case-by-case basis

Target Audience

The primary target audience includes biopharmaceutical analysts, investment firms, and research teams who require efficient access to and analysis of comprehensive clinical trial data for competitive intelligence, investment decisions, and research strategies.

Revenue Model

Sleuth is priced as an annual retainer, with specific pricing dependent on factors such as custom use cases and the number of licenses.